Rajesh Krishnan
Chief Tech/Sci/R&D Officer bij ONCTERNAL THERAPEUTICS, INC.
Vermogen: 19 809 $ op 31-03-2024
Profiel
Rajesh Krishnan is currently the Chief Technology Officer at Oncternal Therapeutics, Inc. Prior to his current position, he held the role of Head-Biologics Drug Substance Process Development at Gilead Sciences, Inc. from 2012 to 2017.
He also served as the VP-Process Development & Manufacturing Sciences at Dynavax Technologies Corp.
from 2018 to 2019.
Dr. Krishnan completed his undergraduate degree at Princeton University and holds graduate and doctorate degrees from the University of California, Davis.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 14-02-2024 | 2 201 ( 0.07% ) | 19 809 $ | 31-03-2024 |
Actieve functies van Rajesh Krishnan
| Bedrijven | Functie | Begin |
|---|---|---|
| ONCTERNAL THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | - |
Eerdere bekende functies van Rajesh Krishnan
| Bedrijven | Functie | Einde |
|---|---|---|
| DYNAVAX TECHNOLOGIES CORPORATION | Corporate Officer/Principal | 01-01-2019 |
| GILEAD SCIENCES, INC. | Corporate Officer/Principal | 01-01-2017 |
Opleiding van Rajesh Krishnan
| Princeton University | Undergraduate Degree |
| University of California, Davis | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| GILEAD SCIENCES, INC. | Health Technology |
| DYNAVAX TECHNOLOGIES CORPORATION | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
| Oncternal Therapeutics, Inc. |
